青光眼针灸假针刺随机对照试验报告质量评价
该系统评价检索10个数据库至2025年8月,纳入6项青光眼针灸假针刺RCT,用CONSORT 2025、STRICTA和SHARE清单评估报告质量。总体报告质量欠佳,CONSORT、STRICTA和SHARE平均报告率分别为39.7%、62.7%和35.1%,假针刺对照细节报告亟待改善。
要点
- 青光眼针灸假针刺RCT仅6项,CONSORT中位OQS为16项。
- SHARE清单平均报告率仅35.1%,假针刺对照细节报告不足。
- 建议未来RCT严格遵循CONSORT、STRICTA和SHARE进行报告。
核心结论
- 青光眼针灸假针刺RCT的总体报告质量欠佳,尤其假针刺对照的详细信息报告亟待改善。
- 建议未来相关RCT严格遵循CONSORT声明、STRICTA标准和SHARE清单进行规范化报告。
研究设计与样本
- 系统检索PubMed、Cochrane Library、Embase、Scopus、Web of Science、EBSCO、CNKI、万方、SinoMed和VIP共10个数据库。
- 检索时限为建库至2025年8月,纳入中英文青光眼针灸干预RCT。
- 最终纳入6项符合预设标准的假针刺对照RCT。
- 采用CONSORT 2025、STRICTA和SHARE清单评估总体质量评分(OQS),用Cohen's κ系数评价评价者间一致性。
主要发现
- 初检获1289条相关记录,经逐步筛选后符合标准的假针刺对照RCT仅6项。
- CONSORT评估中,6项RCT的OQS中位数为16项(范围10-23)。
- CONSORT清单中9项(21%)阳性率大于80%,20项(48%)阳性率低于20%。
- STRICTA评估中,OQS中位数为10.5项(范围8-14);6项(35%)阳性率大于80%,1项(6%)低于20%。
- SHARE评估中,OQS中位数为6.5项(范围3-10);3项(18%)报告率大于80%,10项(53%)低于20%;CONSORT、STRICTA和SHARE总体平均报告率分别为39.7%、62.7%和35.1%。
关键数值与推荐
- CONSORT清单中阳性率大于80%的条目为9项(21%),低于20%的条目为20项(48%)。
- STRICTA清单中阳性率大于80%的条目为6项(35%),低于20%的条目为1项(6%)。
- SHARE清单中报告率大于80%的条目为3项(18%),低于20%的条目为10项(53%)。
临床怎么用
- 开展青光眼针灸假针刺RCT时,应参照SHARE清单详细报告假针刺对照的设置信息。
- 报告时应同时遵循CONSORT 2025和STRICTA标准,以提升整体报告透明度。
局限性
- 符合预设标准的假针刺对照RCT仅6项,样本量有限。
- 评价者间一致性以Cohen's κ系数评估,但原文未报告具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically evaluate the reporting quality of sham-acupuncture-randomized controlled trials (RCTs) investigating acupuncture intervention for glaucoma. METHODS: A systematic search was conducted in PubMed, the Cochrane Library, Embase, Scopus, Web of Science, EBSCO, China National Knowledge Infrastructure (CNKI), Wanfang Database, SinoMed, and China Science and Technology Journal Database (VIP) for Chinese and English RCTs on acupuncture intervention for glaucoma published from database inception until August 2025. The Consolidated Standards of Reporting Trials 2025 (CONSORT), Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA), and the Sham Acupuncture Reporting Guidelines and a Checklist in Clinical Trials (SHARE) were used by the investigators to assess the Overall Quality Score (OQS) of the RCTs that met the pre-defined inclusion criteria. Inter-rater agreement was evaluated using Cohen's κ coefficient. RESULTS: The systematic search initially identified 1289 relevant records. After a stepwise screening process, it was found that RCTs utilizing sham acupuncture controls were very limited; consequently, only 6 RCTs meeting the pre-defined criteria were ultimately included. According to the CONSORT statement, the median OQS for the 6 RCTs was 16 items (range: 10-23). Among all CONSORT items, the positive rate for 9 items (21%) was greater than 80%, while for 20 items (48%) it was below 20%. Based on the STRICTA guidelines, the median OQS for the 6 RCTs was 10.5 items (range: 8-14). For the STRICTA guidelines, the positive rate for 6 items (35%) was greater than 80%, and for 1 item (6%) it was below 20%. According to the SHARE guidelines, the median OQS for the 6 RCTs was 6.5 items (range: 3-10). For the SHARE checklist, 3 items (18%) had a reporting rate > 80%, while 10 items (53%) had a rate < 20%. The overall average reporting rates based on CONSORT, STRICTA, and SHARE were 39.7%, 62.7%, and 35.1%, respectively. CONCLUSION: The current reporting quality of sham acupuncture RCTs on acupuncture intervention for glaucoma is generally suboptimal. There is a particular and urgent need to improve the reporting of detailed information regarding the sham acupuncture control. It is recommended that future relevant RCTs strictly adhere to the CONSORT statement, STRICTA standards, and SHARE checklist for standardized reporting.
引用
- Lei YF, Huang XY, Xue SY, et al. Reporting quality assessment of sham acupuncture randomized controlled trials for acupuncture intervention in glaucoma. Complement Ther Med. 2026. PMID: 42880426. doi:10.1016/j.ctim.2026.103452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。